In the study, IW-1701 demonstrated the expected cardiovascular pharmacodynamic effects, proof of mechanism for sGC stimulation, a dose range that was well tolerated in healthy volunteers as a
The work, published online today in the journal Science, highlights the remarkable speed of Adimab’s recently launched single B cell isolation platform, and constitutes the largest panel of
The headline data dose-setting trial for the vaccine, GrassMATAMPL, is anticipated at the end of the first half of this year. The results of that will lead on
The founders of include Pliant Therapeutics researchers from the University of California, San Francisco (UCSF) who have discovered crucial insights into the biology behind fibrosis and The researchers
During the trial, patients given 1.8 mg and 1.2 mg doses of the beloranib drug experienced 12.7% and 13.5% reduction in body weight, respectively. Patients given a placebo
The agency’s letter stated that the company’s application was not sufficiently complete and it is seeking additional supporting information. There was no comment on the acceptability of the
The designation, which is meant to expedite the development of therapies that provide benefits over existing options, was based on an early clinical data from a phase I
Inovio is developing its Zika vaccine with GeneOne Life Sciences and academic collaborators. In the pre-clinical study, Inovio’s SynCon vaccine technology was used to synthetically generate DNA vaccine
Blood banks in the US have been urged to reject donations from people who have traveled to areas where the Zika virus is active or from those who
The endpoint was met at week 12 against placebo achieved p value of <0.0001. Zilretta also demonstrated significant analgesia against placebo at weeks 1 through 16. Flexion said
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.